Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) shares gapped down before the market opened on Friday after Needham & Company LLC lowered their price target on the stock from $53.00 to $52.00. The stock had previously closed at $21.43, but opened at $19.00. Needham & Company LLC currently has a buy rating on the stock. Rocket Pharmaceuticals shares last traded at $18.67, with a volume of 302,016 shares traded.
RCKT has been the topic of several other research reports. William Blair reissued an “outperform” rating on shares of Rocket Pharmaceuticals in a report on Monday, June 3rd. UBS Group lowered their price target on shares of Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, March 1st. Finally, The Goldman Sachs Group began coverage on shares of Rocket Pharmaceuticals in a research report on Tuesday, April 2nd. They issued a “neutral” rating and a $39.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $52.13.
Check Out Our Latest Report on Rocket Pharmaceuticals
Insider Activity at Rocket Pharmaceuticals
Institutional Investors Weigh In On Rocket Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the business. Annandale Capital LLC bought a new stake in shares of Rocket Pharmaceuticals in the 3rd quarter worth approximately $66,000. Tower Research Capital LLC TRC increased its holdings in shares of Rocket Pharmaceuticals by 105.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,557 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 1,829 shares in the last quarter. Old Well Partners LLC acquired a new stake in shares of Rocket Pharmaceuticals during the 4th quarter valued at $200,000. Capstone Investment Advisors LLC bought a new stake in shares of Rocket Pharmaceuticals during the 4th quarter worth $217,000. Finally, Amalgamated Bank grew its holdings in shares of Rocket Pharmaceuticals by 5.4% in the 4th quarter. Amalgamated Bank now owns 8,653 shares of the biotechnology company’s stock worth $259,000 after acquiring an additional 440 shares during the last quarter. 98.39% of the stock is currently owned by institutional investors.
Rocket Pharmaceuticals Stock Up 0.5 %
The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -7.50 and a beta of 1.08. The company has a quick ratio of 10.47, a current ratio of 10.47 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average price of $22.39 and a 200-day moving average price of $26.00.
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last posted its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.01. During the same period last year, the company posted ($0.73) EPS. As a group, equities analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.85 earnings per share for the current fiscal year.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Recommended Stories
- Five stocks we like better than Rocket Pharmaceuticals
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Business Services Stocks Investing
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Compound Interest and Why It Matters When Investing
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.